Anaptysbio
AnaptysBio Inc is a clinical-stage biopharmaceutical enterprise headquartered in San Diego, California. The company focuses on the discovery and development of innovative antibody and therapeutic protein products targeting immunology and inflammatory diseases. Its proprietary somatic hypermutation antibody generation platform enables the rapid creation of novel therapeutics addressing unmet medical needs in dermatology and rheumatology. Principal revenue is earned through pharmaceutical research collaboration agreements, clinical milestone payments, and licensing royalties paid by pharmaceutical partners. AnaptysBio Inc is publicly traded on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in Anaptysbio.
- Legal name
- ANAPTYSBIO
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Anaptysbio
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.09 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)